AMTI Applied Molecular Transport

Applied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare Conference

Applied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 4:20 p.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at . An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit

Investor Relations Contact:

Andrew Chang

Head, Investor Relations & Corporate Communications

Media Contacts:

Alexandra Santos

Wheelhouse Life Science Advisors

Aljanae Reynolds

Wheelhouse Life Science Advisors

 



EN
17/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Applied Molecular Transport

 PRESS RELEASE

Applied Molecular Transport Reports Third Quarter 2023 Financial Resul...

Applied Molecular Transport Reports Third Quarter 2023 Financial Results Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will oper...

 PRESS RELEASE

Applied Molecular Transport Reports Second Quarter 2023 Financial Resu...

Applied Molecular Transport Reports Second Quarter 2023 Financial Results Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development (R&D) expenses. Total R&D expenses for the secon...

 PRESS RELEASE

Applied Molecular Transport Reports First Quarter 2023 Financial Resul...

Applied Molecular Transport Reports First Quarter 2023 Financial Results SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the companyAppointed Shawn Cross to serve as chief executive officer and board chairTahir Mahmood, Ph.D., co-founder and former CEO remains a member of the board and retaine...

 PRESS RELEASE

Applied Molecular Transport Announces Corporate Leadership Change and ...

Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his po...

 PRESS RELEASE

Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 ...

Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch